

Special Issue

Molecular Insights into Depression

Message from the Guest Editors

Psychiatric disorders, including major depressive disorder (MDD), are the leading cause of disability worldwide, affecting an estimated 120 million people around the world. Environmental risk factors such as stress play an important role in the etiology of MDD. Moreover, the high degree of susceptibility suggests a significant contribution to the dysregulation of brain function. The major challenges in managing people with depression are due to the complexity and heterogeneity of this disorder, the poor response of some sufferers to available treatments, and a lack of objective biomarkers. This Special Issue will collate studies of depression-related research focusing on several aspects, including, but not limited to, depression, stress, neural circuits, animal models, therapeutic strategies, biomarkers of depression, behavioral despair, anhedonia, and antidepressants, as well as psychiatric disorders. Both original research and review articles are welcome. We warmly encourage you to propose novel functional studies elucidating the molecular mechanisms and pharmacotherapeutic strategies that could help to untangle the complex etiology of psychiatric disorders.

Guest Editors

Dr. Yu-Cheng Ho

Dr. Cheng-Chun Wu

Dr. Ming Tatt Lee

Deadline for manuscript submissions

closed (30 June 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/169826

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).